NEO_PLIN2101 / NeoCura - LARVOL DELTA

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors (clinicaltrials.gov) - P=N/A | N=36 | Recruiting | Sponsor: YueJuan Cheng | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Mar 2025 ➔ Sep 2025

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors (clinicaltrials.gov) - P=N/A | N=36 | Not yet recruiting | Sponsor: YueJuan Cheng

New trial • Oncology • Solid Tumor

Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China (PRNewswire) - "Innovent Biologics...and NeoCura Bio-Medical Technology...jointly announced that they have entered into a strategic collaboration agreement to carry out a clinical study in China on the combination therapy of sintilimab from Innovent and individualized neoantigen vaccine NEO_PLIN2101 from NeoCura. Innovent will collaborate with NeoCura in China to assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the combination therapy using sintilimab from Innovent and NEO_PLIN2101 from NeoCura in cancer patients, to advance the clinical development of combination immunotherapy for multiple solid tumors, and prepare to submit the Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) in the near future."

Licensing / partnership • New trial • Oncology • Solid Tumor